BRPI0506765A - composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição - Google Patents

composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição

Info

Publication number
BRPI0506765A
BRPI0506765A BRPI0506765-0A BRPI0506765A BRPI0506765A BR PI0506765 A BRPI0506765 A BR PI0506765A BR PI0506765 A BRPI0506765 A BR PI0506765A BR PI0506765 A BRPI0506765 A BR PI0506765A
Authority
BR
Brazil
Prior art keywords
substituted
compound
phenyl
lower alkyl
composition
Prior art date
Application number
BRPI0506765-0A
Other languages
English (en)
Inventor
Lynn Resnick
Donna M Huryn
Joan E Sabalski
Joshua D Berkowitz
Anthony Frank Kreft
Dennis Martin Kubrak
Thomas Joseph Caggiano
Koi Michele Morris
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0506765A publication Critical patent/BRPI0506765A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

COMPOSTO OU UM SEU SAL, HIDRATO E/OU PRó-DROGAFARMACêUTICAMENTE ACEITáVEIS, COMPOSIçãO FARMACêUTICA, MéTODOS PARA INIBIR A PRODUçãO DE BETA-AMILóIDE EM UM PACIENTE E PARA TRATAR DE UMA DOENçA, KIT FARMACêUTICO, USO DE UM COMPOSTO OU DE UMA COMPOSIçãO Composto úteis para reduzir os níveis da beta - amilióde são providos. Os compostos têm a estrutura de fórmula Ia: em que R~ 1~ é alquila inferior, alquila inferior substituída fenila,fenila substituída, benzila, benzila substituída, benzilóxi, benzilóxi substituído, ou SO~ 2~ R~ 5~; R~ 5~ é fenila, fenila substituída, heterociclo, heterociclo susbstituído, alquila ou alquila substituída; R~ 2~é alquila inferior, alquila inferior substituída, CF~ 3~ alquenila, alquenila substituída, alquinila, alquinila substitúida, fenila, fenila substituída ou cicloalquila;R~ 3~ é hidrogênio, alquila inferior ou alquila inferior substituída; R~4~ é fenila, fenila substituída, heteroclico, heteroclicosubstituído, tiofeno ou tiofeno substituído; R~ 6~ é hidrogênio, alquila inferior, alquila inferior substituída, CF~ 3~, alquenila, alquenila substituída,alquinila,alquinila substituída, fenila, fenila substituída, cicloalquila ou cicloalquila substituída W,X,Y são independentes CR~ 7~ ou N; e R~ 7~ é hidrogênio, halogênio, alquila inferior ou alquila inferior substituída
BRPI0506765-0A 2004-01-16 2005-01-13 composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição BRPI0506765A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53708604P 2004-01-16 2004-01-16
PCT/US2005/001082 WO2005073198A1 (en) 2004-01-16 2005-01-13 Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole

Publications (1)

Publication Number Publication Date
BRPI0506765A true BRPI0506765A (pt) 2007-05-22

Family

ID=34825912

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0506765-0A BRPI0506765A (pt) 2004-01-16 2005-01-13 composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição

Country Status (11)

Country Link
US (3) US7399778B2 (pt)
EP (1) EP1709003B1 (pt)
JP (1) JP2007517905A (pt)
CN (1) CN1910158A (pt)
AT (1) ATE443701T1 (pt)
AU (1) AU2005207835A1 (pt)
BR (1) BRPI0506765A (pt)
CA (1) CA2552558A1 (pt)
DE (1) DE602005016775D1 (pt)
ES (1) ES2330451T3 (pt)
WO (1) WO2005073198A1 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050010882A (ko) * 2002-06-11 2005-01-28 와이어쓰 베타 아밀로이드 생산의 치환 페닐술폰아미드 저해제
UA82093C2 (uk) 2003-03-31 2008-03-11 Уайт Фтор- та трифторалкіловмісні гетероциклічні сульфонамідні інгібітори утворення бета-амілоїду та їх похідні
CA2552558A1 (en) * 2004-01-16 2005-08-11 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole
JP4836280B2 (ja) * 2004-06-18 2011-12-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 癌を治療するためのキネシンスピンドルタンパク質（ｋｓｐ）阻害剤としてのｎ−（１−（１−ベンジル−４−フェニル−１ｈ−イミダゾール−２−イル）−２，２−ジメチルプロピル）ベンズアミド誘導体および関連化合物
EP1984347A1 (en) * 2006-02-17 2008-10-29 Wyeth a Corporation of the State of Delaware Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
AR059518A1 (es) * 2006-02-17 2008-04-09 Wyeth Corp Metodos para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios
JP2009534365A (ja) * 2006-04-21 2009-09-24 アストラゼネカ アクチボラグ Ａｄｇ受容体修飾物質として有用なスルホンアミド化合物
CA2649396A1 (en) 2006-04-21 2007-11-08 Wyeth Production of chirally pure amino alcohol intermediates, derivatives thereof, and uses thereof
US7476762B2 (en) * 2006-04-21 2009-01-13 Wyeth Methods for preparing sulfonamide compounds
US7550629B2 (en) * 2006-04-21 2009-06-23 Wyeth Trifluoromethyl-containing phenylsulfonamide beta amyloid inhibitors
EP2073827A4 (en) * 2006-11-03 2012-04-25 Univ Northwestern THERAPY FOR MULTIPLE SCLEROSIS
PA8789601A1 (es) * 2007-07-16 2009-02-09 Wyeth Corp Proceso para la preparación de trifluoralquil-fenil sulfonamidas y de sulfonamidas heterocíclicas
PA8789801A1 (es) * 2007-07-16 2009-02-09 Wyeth Corp Procesos e intermadiarios para la preparacion de compuestos de silfonamida heterocíclica
WO2009012205A1 (en) * 2007-07-16 2009-01-22 Wyeth Inhibitors of beta amyloid production
WO2009089237A1 (en) * 2008-01-11 2009-07-16 Wyeth Compositions containing o-sulfate and o-phosphate containing aryl sulfonamide derivatives useful as beta-amyloid inhibitors
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
EP4088717A1 (en) * 2008-03-27 2022-11-16 Chase Pharmaceuticals Corporation Use and composition for treating dementia
ES2746480T3 (es) 2009-09-18 2020-03-06 Chase Pharmaceuticals Corp Combinación para tratar demencia de tipo Alzheimer
JP2011043839A (ja) * 2010-09-29 2011-03-03 Panasonic Corp レジスト材料及びそれを用いたパターン形成方法
CN102786447A (zh) * 2011-08-01 2012-11-21 四川大学 N,n-二取代芳基磺酰胺类化合物及其制备方法和用途
KR20200065113A (ko) 2012-09-05 2020-06-08 체이스 파마슈티칼스 코포레이션 항콜린 신경보호 조성물 및 그 방법
CA2951784C (en) * 2014-06-10 2022-05-31 Ube Industries, Ltd. N-substituted sulfonamide compound and method for producing same
JP6572890B2 (ja) 2014-06-10 2019-09-11 宇部興産株式会社 ヘテロ芳香族スルホンアミド化合物の製造方法
US10774072B2 (en) 2014-06-10 2020-09-15 Ube Industries, Ltd. Crystal of N-substituted sulfonamide compound
MA42061A (fr) 2015-05-06 2021-03-31 Leidos Biomedical Res Inc Modulateurs de k-ras
WO2018195439A2 (en) 2017-04-20 2018-10-25 The Regents Of The University Of California K-ras modulators
WO2019204505A2 (en) * 2018-04-18 2019-10-24 Theras, Inc. K-ras modulators with a vinyl sulfonamide moiety

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200209D0 (en) * 1992-01-07 1992-02-26 British Bio Technology Compounds
US5766846A (en) 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5968942A (en) 1992-08-25 1999-10-19 G. D. Searle & Co. α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
NZ264143A (en) 1993-08-09 1996-11-26 Lilly Co Eli Use of an aspartyl protease inhibitor to inhibit beta-amyloid peptide production
DE69637307T2 (de) 1995-11-28 2008-02-28 Cephalon, Inc. Aus d-aminosäuren abgeleitete cystein-und serinproteasehemmer
US5703129A (en) 1996-09-30 1997-12-30 Bristol-Myers Squibb Company 5-amino-6-cyclohexyl-4-hydroxy-hexanamide derivatives as inhibitors of β-amyloid protein production
HUP0001383A3 (en) 1996-11-22 2001-11-28 Lilly Co Eli N-(aryl/heteroaryl) amino acid derivatives, pharmaceutical compositions comprising same and their use
WO1999012910A1 (en) * 1997-09-11 1999-03-18 Nissan Chemical Industries, Ltd. Pyrazole compounds and plant disease control agent
MXPA01008606A (es) 1999-02-26 2003-05-05 Merck & Co Inc Compuestos de sulfonamida novedosos y uso de los mismos.
WO2001012189A1 (en) 1999-08-12 2001-02-22 Pharmacia Italia S.P.A. 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
EP1088815A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonyl amino acid derivatives
EP1088821A1 (en) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutically active sulfonamide derivatives
WO2001027108A1 (en) 1999-10-08 2001-04-19 Bristol-Myers Squibb Pharma Company AMINO LACTAM SULFONAMIDES AS INHIBITORS OF Aβ PROTEIN PRODUCTION
CA2404125C (en) 2000-03-20 2011-01-25 Merck Sharp & Dohme Limited Sulphonamido-substituted bridged bicycloalkyl derivatives
AU2001264872A1 (en) * 2000-06-05 2001-12-17 Ortho-Mcneil Pharmaceutical, Inc. Method for synthesis of substituted azole libraries
ES2267853T3 (es) * 2000-12-13 2007-03-16 Wyeth Inhibidroes de sulfonamida heteriociclicos de la produccion de beta amiloides.
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
EP1461332A4 (en) 2001-12-11 2009-10-21 Wyeth Corp PRODUCTION OF ALPHA-AMINO ACIDS AND CHIRALLY PURE ALPHA-AMINO N-SULFONYL ACIDS
DE10163582A1 (de) * 2001-12-21 2003-07-03 Thomson Brandt Gmbh Automatische Verstärkungsregelung für einen Tuner
UA82093C2 (uk) * 2003-03-31 2008-03-11 Уайт Фтор- та трифторалкіловмісні гетероциклічні сульфонамідні інгібітори утворення бета-амілоїду та їх похідні
CA2552558A1 (en) * 2004-01-16 2005-08-11 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production containing an azole

Also Published As

Publication number Publication date
US20100144812A1 (en) 2010-06-10
ES2330451T3 (es) 2009-12-10
AU2005207835A1 (en) 2005-08-11
EP1709003A1 (en) 2006-10-11
EP1709003B1 (en) 2009-09-23
US7674813B2 (en) 2010-03-09
CA2552558A1 (en) 2005-08-11
CN1910158A (zh) 2007-02-07
US20080249150A1 (en) 2008-10-09
JP2007517905A (ja) 2007-07-05
US7399778B2 (en) 2008-07-15
ATE443701T1 (de) 2009-10-15
DE602005016775D1 (de) 2009-11-05
US20050171180A1 (en) 2005-08-04
WO2005073198A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
ATE537175T1 (de) Neue piperazino-dihydrothienopyrimidin-derivate
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
NO20062692L (no) Heterosykliske MEK inhibitorer og fremgangsmater for anvendelse derav
NO20076418L (no) Heterocyclic compounds as agonists for the thyroid receptor
NZ595829A (en) 8-[4-(1-Aminocyclobutyl)phenyl]-9-phenyl[1,2,4]triazolo[3,4-f]-1,6-naphthyridine derivatives
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
TW200612956A (en) Dihydropteridinones for the treatment of cancer diseases
NO20090443L (no) 2-metylmorfolin pyrido-, pyrazo- and pyrimido-pyrimidin derivater
ECSP055867A (es) Derivados de pirrolopirimidina
SG170101A1 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
ATE457988T1 (de) A2a-adenosin-rezeptor-antagonisten
MX2008013836A (es) Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
ATE443701T1 (de) Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
NO20072409L (no) Substituerte n-sulfonylaminobenzyl-2-fenoksy acetamid-forbindelser
ATE384058T1 (de) Thiazolderivate
MY169274A (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
RU2008120850A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
NO20092035L (no) Tiazolylforbindelser anvendbare som kinaseinhibitorer
NO20083058L (no) Cykloheksylsulfonamidderivater med H3 reseptor aktivitet
NO20051303L (no) Nye benzoimidazolderivater nyttige som antiproliferative midler
EA200501703A1 (ru) Применение производных азетидинкарбоксамида в терапии
AR056321A1 (es) COMBINACIONES TERAPÉUTICAS PARA EL TRATAMIENTO O LA PREVENCIoN DE TRASTORNOS PSICoTICOS
ATE495159T1 (de) Diaminocyclohexan- und diaminocyclopentanderivate

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.